CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its Q3 financial results and provide a business update. The company is focused on developing therapies for high unmet medical needs in liver and chronic diseases. CymaBay has received breakthrough therapy designation, PRIority MEdicines status, and orphan drug status for its treatment, seladelpar, targeting primary biliary cholangitis (PBC).

Positive

• Breakthrough therapy designation received for seladelpar.
• PRIority MEdicines status granted by European Medicines Agency.
• Orphan drug status obtained in the U.S. and Europe for seladelpar.

Negative

• None.

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2021 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13723498. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

What is the date of CymaBay Therapeutics' Q3 2021 earnings call?

The earnings call is scheduled for November 10, 2021.

What will CymaBay Therapeutics discuss during the conference call?

The company will discuss its Q3 financial results and provide a business update.

What is seladelpar and its significance to CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis (PBC) and has received several designations from regulatory agencies.

How can I access the live audio webcast of the conference call?

You can access the live and archived webcast on CymaBay's investor website.

What is the stock symbol for CymaBay Therapeutics?

The stock symbol for CymaBay Therapeutics is CBAY.